Common Stock, $0.001 par value
- Symbol
- CORT
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Corcept Therapeutics Incorporated
CORTNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On February 19, 2026, Corcept Therapeutics Incorporated (the “Company”) issued a press release announcing that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals’ marketing of a generic version of Korlym® does not infringe two of the Company’s patents concerning methods of safely co-administering Korlym and drugs that inhibit the…
Press release in this filing
Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals →Company context
For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease.
Current securities
Registered securities in this filing
CORCEPT THERAPEUTICS INC · 8-K · Filed 2026-02-19
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On February 19, 2026, Corcept Therapeutics Incorporated (the “Company”) issued a press release announcing that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals’ marketing of a generic version of Korlym® does not infringe two of the Company’s patents concerning methods of safely co-administering Korlym and drugs that inhibit the CYP3A4 enzyme, including drugs that are commonly prescribed to patients with Cushing’s syndrome. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Filed exhibits (1)
Exhibit 99.1 CONTACT: Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals REDWOOD CITY, Calif., (February 19, 2026) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals’ marketing of a generic version of Korlym® does not infringe two of Corcept’s patents concerning methods of safely co-administering Korlym and drugs that inhibit the CYP3A4 enzyme, including drugs that are commonly prescribed to patients with Cushing’s syndrome. The ruling affirms a December 2023 verdict by the Federal District Court for the District of New Jersey. “We are disappointed in the Court’s ruling,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. “The patents we asserted in this case cover methods of safely treating patients with Cus…
Open exhibit ↗